Aurobindo Pharma has informed about clarification on news item appeared on www.moneycontrol.com & www.bloombergquint.com dated March 5, 2018 -‘US FDA observations - Aurobindo Unit 4 inspected by US FDA from Feb 12-20 and issues 9 observations’.
The above information is a part of company’s filings submitted to BSE.